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Abstract
Background: Nephropathia epidemica (NE) is a Scandinavian type of hemorrhagic fever with renal syndrome caused 
by Puumala hantavirus. The clinical course of the disease varies greatly in severity. The aim of the present study was to 
evaluate whether plasma C-reactive protein (CRP) and interleukin (IL)-6 levels associate with the severity of NE.
Methods: A prospectively collected cohort of 118 consecutive hospital-treated patients with acute serologically 
confirmed NE was examined. Plasma IL-6, CRP, and creatinine, as well as blood cell count and daily urinary protein 
excretion were measured on three consecutive days after admission. Plasma IL-6 and CRP levels higher than the 
median were considered high.
Results: We found that high IL-6 associated with most variables reflecting the severity of the disease. When compared 
to patients with low IL-6, patients with high IL-6 had higher maximum blood leukocyte count (11.9 vs 9.0 × 109/l, P = 
0.001) and urinary protein excretion (2.51 vs 1.68 g/day, P = 0.017), as well as a lower minimum blood platelet count (55 
vs 80 × 109/l, P < 0.001), hematocrit (0.34 vs 0.38, P = 0.001), and urinary output (1040 vs 2180 ml/day, P < 0.001). They 
also stayed longer in hospital than patients with low IL-6 (8 vs 6 days, P < 0.001). In contrast, high CRP did not associate 
with severe disease.
Conclusions: High plasma IL-6 concentrations associate with a clinically severe acute Puumala hantavirus infection, 
whereas high plasma CRP as such does not reflect the severity of the disease.
Background
Nephropathia epidemica (NE) is a Scandinavian type of
hemorrhagic fever with renal syndrome. The causative
agent, Puumala virus (PUUV), is a member of the genus
Hantavirus in the family Bunyaviridae [1]. Other hanta-
viruses causing more severe forms of HFRS include Han-
taan, Seoul, and Dobrava viruses [2]. Many hantaviruses
in North and South America, e.g. Sin Nombre, Andes,
and Black Creek Canal viruses, cause hantavirus pulmo-
nary syndrome (HPS) [2]. The natural host of PUUV is
the bank vole (Myodes glareolus) [3].
Nephropathia epidemica is prevalent in Finland, else-
where in Scandinavia, in Western Russia, in the Balkan
region and also in many parts of W estern Europe [2,4].
Approximately 1000 serological diagnoses of PUUV
infection are made in Finland annually [5]. However, the
seroprevalence in the Finnish population is 5%, implying
that most infections are subclinical or undiagnosed [5].
The clinical severity of NE varies greatly. Host genetics
have been shown to influence the clinical picture [6,7]. It
is clinically characterized by acute fever, headache, back
and abdominal pains, myalgia, nausea, vomiting, and
transient myopia, while hemorrhages are uncommon
[8,9]. Renal involvement causes proteinuria, hematuria
and oliguria, followed by polyuria [8,9]. A minority of
patients needs transient dialysis treatment [8], but com-
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plete recovery is the usual outcome [8,9]. During the
acute phase, an increase in the serum creatinine concen-
tration, thrombocytopenia, anemia, leukocytosis, as well
as moderately elevated erythrocyte sedimentation rate
and C-reactive protein (CRP) values are typical labora-
tory findings [8,9]. In addition, radiological pulmonary
manifestations have been detected in 16-53% of the
patients, and they have been associated with the degree of
acute renal insufficiency [8-12].
The pathogenesis of NE is not completely understood.
An important feature in hantavirus infections is univer-
sally increased capillary permeability [13], but the mecha-
nisms of vascular leakage are unclear. PUUV causes no
cytopathic effects in cultured cells but has a wide cell sus-
ceptibility in vitro [14]. It has been suggested that immu-
nological factors including cytokines are involved in the
pathogenesis of NE [2]. Increased cytokine levels have
been found in the plasma, urine, and tissues of hantavirus
infection patients [15-18]. Infection of cynomolgus
macaques by PUUV also results in increased serum levels
of several cytokines [19]. We have previously found
plasma and urinary levels of interleukin (IL)-6, tumor
necrosis factor-α, IL-1, and IL-1-receptor antagonist to
be increased during the acute phase of NE, so that the
observed levels of IL-6 were exceptionally high [15].
The IL-6 molecule is a multifunctional cytokine
involved in immune responses and inflammation. IL-6 is
the main inducer of CRP production in vitro in cultured
human hepatoma cells [20], but data about the associa-
tions of IL-6 and CRP in vivo is scarce. The known main
functions of CRP are complement activation, enhance-
ment of phagocytosis, and induction of cytokine synthe-
s i s .  A l t h o u g h  p l a s m a  C R P  l e v e l  i s  w i d e l y  u s e d  a s  a n
indicator of the severity of the disease in various infec-
tions, there are no reports associating high CRP levels to
a severe disease in NE or other viral infections. On the
other hand, IL-6 level has been found to be associated to
the severity of the disease in some viral infections, e.g.
influenza [21,22]. Therefore, we studied whether plasma
IL-6 or CRP levels are associated with the severity of NE,
in order to evaluate if IL-6 or CRP are good markers for
disease severity in NE.
Methods
Patients
The study cohort originally consisted of 131 prospec-
tively collected consecutive patients with acute NE
treated at Tampere University Hospital, Finland, between
September 1997 and December 2004. We have previously
studied urinary IL-6 excretion in 70 NE patients treated
during the years 1997-1999 [15], these patients were also
included in the present material. Now plasma IL-6 levels
were measured altogether from 118 patients, who com-
prised the final cohort of the present study, as we did not
have plasma samples for IL-6 determinations from 13
subjects. The median patient age was 40 (ranging 15-71)
years, and 86 (73%) were males.
Thirty-seven (31%) patients had one or more of the fol-
lowing diseases before NE: essential hypertension in 10,
dyslipidemia in six, hypothyreosis in five, coronary artery
disease in four, and bronchial asthma in three; atrial
fibrillation, celiac disease, chronic inflammatory bowel
disease, and hyperplasia of the prostate in two; sick sinus
syndrome treated with pacemaker, diabetes mellitus,
osteoporosis, ankylosing spondylarthritis, aortic valve
disease, mitral valve disease, epilepsy, fibromyalgia, sar-
coidosis, multiple sclerosis, operated melanoma, oper-
ated cancer of vocal cords, operated meningeoma, and
sequelae of renal tuberculosis in one patient each.
The diagnosis of acute PUUV infection was serologi-
cally confirmed in all cases [23]. All subjects gave
informed consent before participation and the study was
approved by the Ethics Committee of Tampere University
Hospital.
Study protocol
All 118 patients were studied during the acute phase of
NE. A detailed past and current medical history was
obtained, and a careful physical examination was per-
formed. Blood samples to analyze plasma IL-6 and CRP,
serum creatinine, and blood cell count, as well as daily
urinary protein excretion were collected on three consec-
utive mornings after hospital admission. Other blood
samples were taken according to the clinical needs of the
patient. The highest and the lowest value of each patient
of the various variables measured during hospitalization
were designated as the maximum and minimum values.
In this study, we have defined high serum creatinine as a
value exceeding the median maximum creatinine among
the study population (193 μmol/l) and thrombocytopenia
as the minimum platelet count equal to or lower than the
median among the study population (66 × 109/l). High
plasma CRP was defined as the maximum CRP value
above the median in the study population (69 mg/l) and
high plasma IL-6 as the maximum IL-6 value higher than
14.05 pg/ml (the median in the study population).
Methods
All blood specimens were obtained between 7:30-9:30 in
the morning. Plasma CRP was analyzed by Hitachi 705 E
Analyzer from 1997 to 1998 and after that by the Roche
Diagnostics CRP method using Cobas Integra analyzer (F.
Hoffman-La Roche Ltd, Basel, Switzerland). Blood cell
count was completed by hematological cell counters by
Bayer. From 1997 to June 1999, serum creatinine was
determined by Vitros (Johnson & Johnson, Rochester,
NY, USA) and after that by Cobas Integra analyzer. Serum
creatinine concentrations showed 10% lower values afterOutinen et al. BMC Infectious Diseases 2010, 10:132
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June 1999 than during the earlier years due to the change
in the determination method. Therefore, in this study the
results of serum creatinine concentrations from Septem-
ber 1997 to June 1999 were multiplied by the coefficient
0.9. Plasma IL-6 concentrations were determined after-
wards from frozen samples by using commercially avail-
able enzyme-linked immunosorbent assays (PeliKine
Compact human IL-6 kits; Central Laboratory of the
Netherlands, Red Cross Blood Transfusion Service,
Amsterdam, The Netherlands), following the manufac-
turer's instructions. Detection limit for the assay was 0.4
pg/ml for IL-6. The patients in this study did not have val-
ues below the detection limit. The 24-hour urinary pro-
tein excretion was measured by the pyrogallolal red
molybdate method (Olli C.; Kone Instruments, Helsinki,
Finland) from 1997 to April 1998 and after that by Cobas
Integra analyzer, from a total of 72 patients. One chest
radiograph was obtained during hospitalization from 77
patients, two from 16 and three from two patients.
Statistical Analysis
In order to describe the data, medians (ranging) were
given for continuous variables and numbers and percent-
ages for categorical variables.
T o evaluate the associations of plasma IL-6 and CRP
values with the severity of NE, we divided the patients
into two groups, first according to the maximum IL-6
value and then according to the maximum CRP value. For
the purposes of further evaluating the effect of plasma IL-
6 and plasma CRP on the severity of the disease, we
divided the patients into four groups: group 1 with low
IL-6 and low CRP (equivalent to or lower than the
median), group 2 with low IL-6 and high CRP (higher
than the median), group 3 with high IL-6 and low CRP,
and group 4 with both high IL-6 and high CRP.
Groups were compared using the Mann-Whitney U-
test or Kruskal-Wallis test, as appropriate. Categorical
data were analyzed by the x2 test or the Fisher's exact test.
C o r r e l a t i o n s  w e r e  c a l c u l a t e d  b y  m e a n s  o f  S p e a r m a n ' s
rank correlation coefficient. We also performed logistic
regression analyses with high serum creatinine, thrombo-
cytopenia, or hospitalization exceeding seven days as
dependent factors and high plasma IL-6 and high plasma
CRP as independent factors in order to further examine
the association of these factors with the severity of the
disease. Age was also included in these models as a con-
tinuous variable. Adjusted odds ratios (OR) and their 95%
confidence intervals (95% CI) were given. All tests were
two-sided, and statistically significant P-values are given.
All analyses were made with the SPSS (version 7.5) statis-
tical software package.
Results
The clinical and laboratory characteristics of the patients
are shown in Table 1. Three (3%) of the total 118 patients
were in clinical shock at admission, and six (5%) required
dialysis treatment during hospital care. Thirty-four of the
patients (29%) had a plasma CRP value higher than 100
mg/l, 59 (50%) had a leukocyte count higher than 10.0 ×
109/l, 34 (29%) had a platelet count lower than 50 × 109/l,
and 88 (75%) had a serum creatinine value higher than
100 μmol/l during the hospital stay. Thirty patients (32%)
presented with pathologic findings in a chest radiograph.
Everyone recovered completely. The median duration of
fever before admission to the hospital was four (ranging
1-14) days.
Table 1: The clinical and laboratory findings in 118 patients with acute Puumala hantavirus infection.
Symptoms and findings Median Ranging
Duration of fever (days) 5 2-15
Duration of hospital stay (days) 7 2-15
SBP min (mmHg) 112 82-162
Change in weight during hospital stay (kg) 2.6 0-12.0
Urinary output min (ml/day) 1520 50-7000
Urinary protein max (g/day) 1.80 0.14-17.78
Creatinine max (μmol/l) 193 65-1285
Platelets min (109/l) 66 3-238
Hematocrit min 0.36 0.25-0.46
Leukocytes max (109/l) 10.0 3.9-31.2
CRP max (mg/l) 69 11-269
IL-6 max (pg/ml) 14.05 1.31-107.00
SBP = systolic blood pressure, min = minimum, max = maximum, CRP = C-reactive protein, IL-6 = interleukin-6.Outinen et al. BMC Infectious Diseases 2010, 10:132
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The median age did not differ between patients with
high plasma IL-6 and patients with low IL-6 (41 years,
ranging 15-65 vs  39 years, ranging 17-71, P  = 0.741).
Forty-four (75%) of the patients with high IL-6 were
males compared with 42 (71%) of the patients with low
IL-6 (P = 0.679). In patients with high plasma CRP, the
median age was higher than in patients with low CRP (46
years, ranging 25-71 vs  38 years, ranging 15-64, P  <
0.001). Forty-two (72%) of the patients with high CRP
were males compared with 44 (73%) of the patients with
low CRP (P = 0.911).
The maximum level of plasma IL-6 associated strongly
with several variables reflecting the severity of the disease
(Figures 1 and 2). Patients who had high IL-6 had lower
minimum urinary output (1040 vs 2180 ml/day, Figure
1A), lower minimum systolic blood pressure (110 vs 115
mmHg, Figure 1B), and a greater change in weight during
hospital care (3.2 vs  2.0 kg, Figure 1C), and they also
stayed longer in hospital than patients with low IL-6 (8 vs
6 days, Figure 1D). Furthermore, patients with high IL-6
had numerically (but not statistically significantly) higher
maximum serum creatinine levels (242 vs  140 μmol/l,
Figure 2A), higher maximum urinary protein excretion
(2.51 vs 1.68 g/day, Figure 2B), higher maximum leuko-
cyte count (11.9 vs 9.0 × 109/l, Figure 2C), lower mini-
mum platelet count (55 vs 80 × 109/l, Figure 2D), and
lower minimum hematocrit (0.34 vs 0.38, P = 0.001) than
patients with low IL-6. The clinical or laboratory vari-
ables between the patients with high and low CRP did not
differ (Figures 1F-H, 2E-H) with the exception of mini-
mum urinary output. Patients with high CRP had slightly
lower minimum urinary output when compared to
patients with low CRP (1400 vs 1700 ml/day, Figure 1E).
The occurrence of a pathologic chest radiograph had
no significant associations with high IL-6 or high CRP.
Twenty patients (38%) with high IL-6 had a pathologic
chest x-ray compared with 10 patients (24%) with low IL-
6 (P = 0.147). Eighteen patients (37%) with high CRP had
a pathologic chest x-ray compared with 12 patients (26%)
with low CRP (P = 0.265).
There was a positive correlation between plasma CRP
and plasma IL-6 levels (r = 0.323, P < 0.001). We also
found a slight positive correlation between maximum
plasma IL-6 and serum creatinine concentrations (r =
0.238,  P  = 0.010), whereas no correlation was found
between maximum plasma CRP and serum creatinine
levels.
Figure 1 The associations of various clinical variables with maximum plasma interleukin-6 and C-reactive protein concentrations in pa-
tients with Puumala hantavirus infection. Data are given as median (thick line), 25th-75th percentile (box), and range (whiskers); outliers have been 
omitted from the figure.Outinen et al. BMC Infectious Diseases 2010, 10:132
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Tables 2 and 3 show the associations of various vari-
ables reflecting the severity of the disease with plasma IL-
6 and CRP levels in patients divided into four groups
according to maximum IL-6 and CRP values. Table 2
shows that especially patients with an IL-6 value higher
than the median, with or without high CRP (groups 3 and
4), had more severe disease as measured with several
clinical parameters. Table 3 shows the occurrence of
shock, dialysis treatment, pathologic findings in a chest x-
ray, high serum creatinine, thrombocytopenia, and hospi-
talization longer than seven days (median) in these four
groups. Significantly fewer patients in group 2 (low IL-6
and high CRP) had high serum creatinine levels com-
pared to the other three groups (group 2 vs group 1, P =
0.048; group 2 vs group 3, P = 0.002; group 2 vs group 4, P
= 0.024). Furthermore, none of the patients in group 2
required dialysis treatment.
Logistic regression analyses were then carried out to
evaluate the associations of high CRP and high IL-6 with
high serum creatinine, thrombocytopenia, or hospitaliza-
tion exceeding seven days. High plasma IL-6 was revealed
as an independent risk factor for high serum creatinine
(OR 3.2, 95% CI 1.4-7.3, P = 0.005), whereas high plasma
CRP was found to be a protective factor (OR 0.3, 95% CI
0.1-0.7, P = 0.009) in this model. High plasma IL-6 was
also found to be an independent risk factor for thrombo-
cytopenia and hospitalization exceeding seven days (OR
3.6, 95% CI 1.6-8.0, P = 0.002, and OR 4.5, 95% CI 1.9-
10.8, P  < 0.001, respectively) in models including high
plasma IL-6, high plasma CRP, and age. High plasma CRP
did not have a significant association with these factors
(data not shown).
As the patients with NE sought medical assistance at
different time intervals from the onset of fever, the
plasma CRP and IL-6 samples were also taken at different
periods from the onset. From the majority of patients
(66%) we had both CRP and IL-6 samples taken 5 days
from the onset of fever. In this subgroup of 78 patients
the main results remained the same: when compared to
patients with low IL-6, patients with high IL-6 had higher
creatinine levels, higher leukocyte count, greater change
in weight, as well as a lower platelet count, hematocrit,
and urinary output. They also stayed longer in hospital
than patients with low IL-6. High CRP five days after the
onset of fever had no associations with the variables
reflecting the severity of NE (data not shown).
Figure 2 The associations of laboratory variables with maximum plasma interleukin-6 and C-reactive protein concentrations in patients 
with Puumala hantavirus infection. Data are given as median (thick line), 25th-75th percentile (box), and range (whiskers); outliers have been omitted 
from the figure.Outinen et al. BMC Infectious Diseases 2010, 10:132
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Discussion
The present study with 118 consecutive prospectively
collected hospitalized patients is by far the largest study
concerning inflammatory parameters, i.e. IL-6 and CRP,
in acute Puumala hantavirus infection. The present data
showed that high plasma IL-6 is associated with clinically
severe NE. High IL-6 was found to be an independent risk
factor for impaired renal function, thrombocytopenia,
and longer hospitalization, when examined together with
high CRP and age. Surprisingly, the results also suggested
that high plasma CRP might have a protective effect on
renal function, but the data must be interpreted with cau-
tion.
We found that maximum plasma IL-6 was associated
with the severity of renal insufficiency, blood leukocyto-
sis and thrombocytopenia. It also associated strongly
with the duration of hospitalization. We have previously
studied plasma IL-6 concentrations in a cohort of 70 NE
patients and found IL-6 levels to be increased [15]. In that
earlier study, there was no correlation between plasma
IL-6 levels and serum creatinine, but in the present larger
study we did find a correlation between the levels of these
two variables.
Previously, Linderholm and co-workers have studied 15
NE patients and detected elevated IL-6 plasma levels in
all cases [17]. They also found a significant correlation
between maximum levels of IL-6 and serum creatinine in
concordance with our results. Takala and co-workers
have studied 19 NE patients and 13 patients with other
viral infections and detected an inverse correlation of
Table 2: The clinical and laboratory variables in patients with Puumala hantavirus infection divided into four groups 
according to maximum plasma interleukin-6 and C-reactive protein levels.
Group 1 (N = 37)
CRP ≤ 69 mg/l
IL-6 ≤ 14.05 pg/ml
Group 2 (N = 22)
CRP > 69 mg/l
IL-6 ≤ 14.05 pg/ml
Group 3 (N = 23)
CRP ≤ 69 mg/l
IL-6 > 14.05 pg/ml
Group 4 (N = 36)
CRP > 69 mg/l
IL-6 > 14.05 pg/ml
P-value
Age (years) 38 (17-63) 51 (26-71) 36 (15-64) 45 (25-65) 0.013
Hospital stay (days) 6 (2-15) 6 (3-10) 7 (4-13) 8 (3-14) 0.003
SBP min (mmHg) 117 (82-162) 112 (93-149) 110 (85-140) 112 (86-158) 0.092
Change in weight (kg) 2.1 (0-9.9) 1.3 (0-4.7) 2.8 (0-12.0) 3.3 (0-9.9) 0.023
Urinary output min (ml/day) 2230 (350-7000) 2050 (200-4940) 1040 (50-4900) 1045 (50-3325) < 0.001
Urinary protein max (g/day) 1.43 (0.14-5.59) 2.03 (0.57-4.31) 6.05 (0.30-10.00) 1.72 (0.30-17.78) 0.003
Creatinine max (μmol/l) 193 (65-917) 114 (68-878) 256 (88-1285) 230 (70-1156) 0.073
Platelets min (109/l) 80 (3-238) 84 (19-159) 59 (9-139) 54 (13-187) 0.001
Hematocrit min 0.38 (0.29-0.43) 0.38 (0.29-0.44) 0.34 (0.25-0.43) 0.35 (0.25-0.46) 0.007
Leukocytes max (109/l) 9.0 (3.9-31.2) 9.2 (5.4-18.6) 11.0 (5.1-23.2) 12.2 (7.1-26.8) 0.011
Values are expressed as medians (ranging). SBP = systolic blood pressure, min = minimum, max = maximum, CRP = plasma C-reactive protein, IL-
6 = plasma interleukin-6.
Table 3: Categorical variables associated with the severity of the disease in nephropathia epidemica patients, divided into 
four groups according to maximum plasma interleukin-6 and C-reactive protein levels.
Group 1 (N = 37)
CRP ≤ 69 mg/l
IL-6 ≤ 14.05 pg/ml
Group 2 (N = 22)
CRP > 69 mg/l
IL-6 ≤ 14.05 pg/ml
Group 3 (N = 23)
CRP ≤ 69 mg/l
IL-6 > 14.05 pg/ml
Group 4 (N = 36)
CRP > 69 mg/l
IL-6 > 14.05 pg/ml
P-value
Gender (males) 28 (76%) 14 (64%) 16 (70%) 28 (78%) 0.645
Shock 0 (0%) 0 (0%) 1 (4%) 2 (6%)
Dialysis treatment 1 (3%) 0 (0%) 2 (9%) 3 (8%)
Pathologic chest x-ray 6 (23%) 4 (25%) 6 (30%) 14 (42%) 0.390
Hospital stay > 7 days 7 (19%) 5 (23%) 11 (48%) 19 (53%) 0.007
Creatinine max > 193 μmol/l 18 (49%) 5 (23%) 16 (70%) 19 (53%) 0.017
Platelets min ≤ 66 × 109/l 14 (38%) 7 (32%) 13 (57%) 27 (75%) 0.002
Values are expressed as numbers and percentages. CRP = plasma C-reactive protein, IL-6 = plasma interleukin-6, max = maximum, min = 
minimum.Outinen et al. BMC Infectious Diseases 2010, 10:132
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serum IL-6 concentrations in NE patients with mean
arterial pressure and minimum platelet count [24].
Plasma levels of IL-6 have been reported to associate with
the severity of the disease also in influenza and Japanese
encephalitis [21,22,25]. Studies of IL-6 in respiratory syn-
cytial virus infection and Dengue virus infection have
produced controversial results [26-29]. In acute renal fail-
ure, it has been demonstrated that plasma IL-6 levels are
elevated and that high levels predict mortality [30,31].
As far as we know, this is the first report suggesting that
CRP might act as a protective factor for renal function in
infectious diseases. Previously, it has been shown in mice
that CRP prevents and reverses proteinuria in accelerated
nephrotoxic nephritis [32-34]. It has also been reported
that genetics associated with reduced CRP production
predispose to the development of systemic lupus
erytematosus [35]. This has been attributed to the ability
of CRP to prevent the deposition of immune complexes
and enhance their phagocytosis. It should be noted that
immune complexes have also been found in NE patients
[36]. Reduced deposition and enhanced phagocytosis of
immune complexes could be the mechanism by which
high CRP protects renal function in NE. In viral infec-
tions, there are no reports of CRP concentrations affect-
ing the severity of the disease. In bacteremia and sepsis,
the results concerning CRP as a predictor of clinical out-
come are controversial. A year 2005 review concludes
that the ability of CRP level to reflect the severity of sep-
sis may be limited [37].
Finally, there was a positive correlation between maxi-
mum IL-6 and CRP levels in the present study, which can
be explained by the fact that IL-6 induces the production
of CRP. However, high IL-6 concentration was associated
with more severe disease, whereas high CRP level, in con-
trast, was associated with less severe renal impairment.
This finding can probably be explained by the diverse bio-
logical influences of IL-6 and CRP.
Conclusions
High plasma IL-6 concentration is associated with clini-
cally severe acute NE and could be used as a marker of
the severity of the disease. On the other hand, high CRP
as such does not indicate a severe form of NE.
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